Does an ovarian mass mean cancer?
No, an ovarian mass—or “ovarian lesion”—is not synonymous with cancer. The term “ovarian mass” (often referred to colloquially as a “mass” or “lesion”) is a broad radiologic and clinical descriptor for any abnormal growth or collection of tissue in or on the ovary. These can be cystic, solid, or mixed, and may arise from normal physiologic processes, benign conditions, borderline tumors, or malignant neoplasms.
Common benign causes include functional ovarian cysts (e.g., follicular or corpus luteum cysts), endometriomas, dermoid cysts (mature teratomas), and serous or mucinous cystadenomas. Many of these are asymptomatic, discovered incidentally during imaging or routine pelvic examination, and often resolve spontaneously—especially functional cysts in premenopausal individuals.
Malignant ovarian tumors account for a minority of ovarian masses, particularly in younger patients. Risk increases with age, especially after menopause, and is elevated in individuals with certain genetic predispositions (e.g., BRCA1/BRCA2 pathogenic variants, Lynch syndrome) or a strong family history of ovarian, breast, or colorectal cancer. Features that raise concern for malignancy include solid components, papillary projections, thick septations, ascites, elevated serum CA-125 (particularly in postmenopausal women), and imaging characteristics suggestive of invasion or metastasis.
Accurate diagnosis requires integration of clinical assessment, imaging (typically transvaginal ultrasound with Doppler, sometimes supplemented by MRI or CT), tumor markers (e.g., CA-125, HE4, AFP, LDH, hCG depending on suspected histology), and, when indicated, surgical evaluation. Definitive diagnosis relies on histopathologic examination of tissue—either via biopsy (less common for primary ovarian lesions due to risk of rupture and spillage) or, more typically, through surgical excision and comprehensive staging.
If an ovarian mass is identified, management is individualized based on patient age, symptoms, imaging features, biomarker levels, and risk stratification tools such as the Risk of Malignancy Index (RMI) or ADNEX model. Observation with serial imaging may be appropriate for simple, small, asymptomatic cysts in premenopausal women, whereas complex or enlarging masses—especially in postmenopausal patients—warrant prompt gynecologic oncology referral.